The latest phase 1 clinical trial data of Nexvax2, a vaccine to protect celiac patients from the side effects of accidentally taking gluten, has shown conclusive conclusions, according to rresults of a study published in the medical journal The Lancet Gastroenterology and Hepatology.
Researchers at ImmusanT, the makers of the vaccine, performed two randomized, phase I, double-blind, placebo-controlled trials of the efficacy and side effects of Nexvax2, a vaccine believed to protect celiac patients from accidental consumption. gluten.
Patients were protected by the vaccine
The results revealed that patients treated with Nexvax2 in these trials did indeed exhibit an alteration in the immune response to gluten with no apparent duodenal damage. Nexvax2 reduced the reactivity of specific T cells in response to gluten in celiac disease.
“The results of these two Phase 1 studies suggest that Nexvax2, a therapeutic vaccine evaluated for the management of celiac disease, demonstrates relevant bioactivity and excellent results,” said Robert Anderson, Scientific Director of ImmusanT. In addition, patients treated with Nexvax2 in these trials experienced an alteration in the gluten-recalled immune response without apparent duodenal damage. The results indicate that Nexvax2 reduced the responsiveness of gluten-specific T cells to stimulation in celiac disease. .
The celiac disease is an immune gastrointestinal disease caused by dietary gluten. About 90% of patients with celiac disease carry the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition gene. At present, there is no pharmaceutical treatment for this condition and the only method of management is to maintain a gluten free diet which is expensive and often impractical.
Read also:
Gluten allergy: a virus involved?
Celiac disease is believed to promote anorexia
Gluten sensitivity: not to be confused with intolerance!
